HMMR inhibition by 4-methylumbelliferone is effective in preclinical hepatocellular carcinoma models.
Abstract
, 4-MU treatment significantly inhibited tumor growth in a HepG2 xenograft model, resulting in a 44% reduction in tumor volume by day 20 and an 80% decrease in HMMR expression in tumor tissues. These results demonstrate that HMMR promotes growth and migration in HCC, and targeting HMMR effectively inhibits both parental and drug-resistant HCC cells. Additionally, our findings suggest that 4-MU, an approved drug for biliary tract disorders, holds promise as a repurposed therapeutic candidate for HCC treatment.
Fields of Study & Subjects
Cancer
Hypoxia
and Metabolism
Publication details
- Journal / source
- PubMed
- Volume
- 41
- Issue
- 1
- Pages
- 151–157
- Publication date
- 1 January 2026
- Language
- EN